Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...
cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...
The updated ACS guideline adds 3 tests to its recommended screening options, reflecting advances in disease detection and a broader public health effort to expand access and lower barriers to ...
BRISBANE, Calif., May 27, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, welcomes the inclusion of blood-based testing in the American Cancer ...
A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results